Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • In Brief
  • Published:

Prostate cancer

Survival nomogram for men with progressive mCRPC

Nature Reviews Urology volume 11, page 64 (2014)Cite this article

Subjects

A nomogram for predicting overall survival of men with progressive metastatic castration-resistant prostate cancer (mCRPC) who receive second-line chemotherapy following first-line docetaxel has been developed using data from the TROPIC phase III trial of mitoxantrone versus cabazitaxel (n = 755), and validated using data from the SPARC trial of satraplatin versus placebo (n = 488). Two novel prognostic variables were among the nine used in the nomogram—time since last docetaxel use and duration of hormonal use.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

References

  1. Halabi, S. et al. Prognostic model predicting metastatic castration-resistant prostate cancer survival in men treated with second-line chemotherapy. J. Natl Cancer Inst. 10.1093/jnci/djt280

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Survival nomogram for men with progressive mCRPC. Nat Rev Urol 11, 64 (2014). https://doi.org/10.1038/nrurol.2013.311

Download citation

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/nrurol.2013.311

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing